Biotechniques

1. Information regarding use of intravenous peramivir under an emergency use authorization

2. Information on availability of renal dosing for peramivir

3. Updated oseltamivir dosing instructions for children younger than 1 year of age based on weight

4. Antiviral treatment and chemoprophylaxis considerations for patients vaccinated with 2009 H1N1 and seasonal influenza vaccines

5. Guidance on early empiric antiviral treatment for patients with progressive or severe influenza-like illness, regardless of underlying medical conditions

6. Guidance on early empiric antiviral treatment patients with underlying medical conditions placing them at risk for complications

7. Clarification of treatment considerations for patients with illness longer than 48 hours

These recommendations focus on the use of antiviral medications for the treatment and chemoprophylaxis of influenza.  As of December 4, 2009, influenza A (H1N1) virus (2009 H1N1), is the strain responsible for >99% of influenza in the U.S. during the 2009-2010 influenza season.  For information about other influenza viruses refer to CDC's Website.  These recommendations were last updated on December 4, 2009, and will be updated periodically as new information becomes available.

On this Page

· Objective

· Introduction

· Treatment of confirmed or suspected influenza

· Antiviral Chemoprophylaxis of exposed individuals

· Antiviral drug use for control of influenza outbreaks in institutions

· Specific regimens for treatment and chemoprophylaxis of influenza

· Antiviral prescription and dispensing considerations

· Adverse events and contraindications

· Further information